BIRC5 and neoplasm: Screening of an apoptotic antibody array using lysates of UM-SCC47 or SCC25 HNSCC cells treated for 16 hours with 30 μmol/L SSTNIGF1R revealed a significant change in apoptotic markers when the tumor cells were treated with the peptide, as evidenced by significant increases in activated caspase 3 and PARP, and reduced levels of survivin and phosphorylated Erk, Akt, and Bad (Fig. 4B).